Healthcare - Biotechnology - NASDAQ - CH
$ 47.25
0.854 %
$ 4.03 B
Market Cap
-18.03
P/E
INCOME STATEMENT
371 M
REVENUE
-223 M
OPERATING INCOME
-154 M
NET INCOME
EFFICIENCY
Earnings Waterfall
CRISPR Therapeutics AG
| Revenue | 371 M |
| Cost Of Revenue | 130 M |
| Gross Profit | 241 M |
| Operating Expenses | 463 M |
| Operating Income | -223 M |
| Other Expenses | -68.9 M |
| Net Income | -154 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Revenue | 371.2 | 0.4 | 913.1 | 0.5 | 289.6 | 3.1 | 41.0 | 5.2 | 0.2 | 0 |
| GROSS PROFIT | ||||||||||
| Cost Of Revenue | 130.2 | 110.2 | 18.0 | 269.4 | 179.4 | 113.8 | 69.8 | 42.2 | 12.6 | 1.5 |
| Gross Profit | 241.0 | (109.8) | 895.1 | (268.9) | 110.2 | (110.6) | (28.8) | (37.1) | (12.3) | (1.5) |
| OPERATING INCOME | ||||||||||
| Operating Expenses | 463.5 | 563.3 | 539.6 | 355.0 | 242.8 | 162.1 | 105.6 | 73.3 | 26.0 | 6.6 |
| Selling, General and Administrative Expenses | 76.2 | 102.5 | 102.8 | 88.2 | 63.5 | 48.3 | 35.8 | 31.1 | 13.4 | 5.1 |
| Research and Development Expenses | 387.3 | 461.6 | 438.6 | 266.9 | 179.4 | 113.8 | 69.8 | 42.2 | 12.6 | 1.5 |
| Operating Income | (222.5) | (673.2) | 373.5 | (354.4) | 46.7 | (158.9) | (64.6) | (68.1) | (25.7) | (6.6) |
| PRE-TAX INCOME | ||||||||||
| Interest Income Expense | 0 | (46.8) | 0 | 0 | 0 | 0 | 0 | 8.1 | 0.1 | 0 |
| Total Other Income | 71.8 | 22.7 | 6.0 | 6.4 | 20.6 | (5.5) | (2.0) | 45.4 | 92 K | (0.2) |
| Pre-Tax Income | (150.7) | (650.5) | 379.5 | (348.1) | 67.3 | (164.4) | (66.6) | (22.7) | (25.8) | (6.9) |
| NET INCOME | ||||||||||
| Tax Provision | 2.9 | (0.3) | 1.9 | 0.8 | 0.4 | 0.6 | 1.7 | 0.5 | 7 K | 63 K |
| Net Income | (153.6) | (650.2) | 377.7 | (348.9) | 66.9 | (165.0) | (68.4) | (23.2) | (25.8) | (6.8) |
| EPS | 1.94 | 8.36 | 4.97 | 5.29 | 1.23 | 3.44 | 1.71 | 1.89 | 0.88 | 0.23 |